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ABSTRACT 
Background: Despite increasing use of robotic surgery for rectal cancer, few series have 
been published from the practice of generalizable US surgeons.   
Methods: We performed a retrospective chart review for 71 consecutive patients who 
underwent robotic low anterior resection (LAR) or abdominoperineal resection (APR) for 
rectal adenocarcinoma between 2010-2014.  
Results: We identified 46 LARs (65%) and 25 APRs (35%).  Median procedure time was 
219 minutes (IQR 184-275) and mean blood loss 164.9 cc (SD 155.9 cc).  Radial margin 
was negative in 70/71 (99%) patients.  Total mesorectal excision integrity was 
complete/near complete in 38/39 (97%) of graded specimens. A mean of 16.8 (SD+/- 8.9) 
lymph nodes were retrieved.  At median follow up of 21.9 months, there were no local 
recurrences.   
Conclusions: Robotic proctectomy for rectal cancer was introduced in to a typical 
colorectal surgery practice by a single surgeon with a low conversion rate, low 
complication rate, and satisfactory oncologic outcomes. 
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INTRODUCTION 
 The expansion of minimally invasive surgery into rectal cancer has largely been 
based on case series reports from highly specialized units and extrapolation from the 
laparoscopic colectomy for cancer literature [1-5].  Concerns about oncologic safety and 
the technical difficulty of the procedures have slowed wide adoption.  The results from 
two recent randomized controlled studies comparing minimally invasive to open 
resection for rectal cancer have inspired even greater caution in regard to the use of 
laparoscopy for rectal cancer [6, 7].  Although robotic procedures were incorporated into 
the minimally invasive arm of one trial [6], some authors have suggested that the unique 
technical aspects of the robotic platform may improve upon the short term and technical 
outcomes observed to be inadequate in these trials [8].   
Before advantages of robotic technique for rectal cancer can be demonstrated, 
consideration of the effect of formal robotic training and learning curves among early 
cases must be better studied.  Traditionally, these studies have been hampered at least in 
part due to a lack of experience from the practice of generalizable US surgeons where 
formal robotic training in colorectal surgery is in its infancy. 
 We sought to critically evaluate the short- and long-term outcomes of robotic 
rectal cancer resections by a single colorectal surgeon, self-taught after completion of 
formal training, in an academic institution without a specialized robotics focus. 
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METHODS 
Patients 
 Following institutional review board approval, retrospective chart review was 
performed on consecutive patients undergoing robotic proctectomy for rectal 
adenocarcinoma from 2010-2014 at our institution which include the first robotic cases 
performed by the author.  Patients were excluded for non-cancer indications for 
proctectomy, incomplete records for review, patients lost to follow up, and operative 
technique involving initial laparoscopic or open surgery.  We analyzed 85 patients with 
14 excluded according to the exclusion criteria for a final cohort of 71 patients.  Patients 
who underwent intended robotic proctectomy converted to open procedure were included 
in the analysis.  Patients all underwent appropriate preoperative staging according to the 
American Joint Committee on Cancer (AJCC) 7th edition, and patients with locally 
advanced tumors were treated with neoadjuvant chemoradiation in accordance with 
contemporary practice guidelines at the time of treatment.  Patients were classified 
according to type of operation with sphincter preserving operations categorized as low 
anterior resection (LAR), which including low anterior resection with ileostomy or 
colostomy, or anterior resection without proximal diversion, and sphincter sacrificing 
resection classified as abdominal perineal resection (APR).  Robotic proctectomy was 
performed via a hybrid approach.  The splenic flexure was mobilized and the inferior 
mesenteric artery ligated laparoscopically, after which the robot was docked for the rectal 
dissection.  Perineal dissection for APR was performed in the lithotomy position.  
Patients who underwent LAR were routinely diverted with loop ileostomy if they had 
preoperative chemoradiation and the anastomosis was below the peritoneal reflection. 
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 Data on type of procedure performed, preoperative variables including staging 
and comorbid conditions, operative variables including operative time, conversion to 
open, lymph nodes retrieved, grade of TME excision, blood loss, and blood transfusion, 
and postoperative variables including length of stay, 30 day complications, and oncologic 
outcomes recurrence, disease specific, and overall survival were obtained from the 
medical record and review of the American College of Surgeons-National Surgical 
Quality Improvement Program database [9].  Total mesorectal excision (TME) integrity 
was graded by a pathologist.   
Statistical Analysis 
Depending on variable distribution, Student T or Mann-Whitney-Wilcoxon test 
was used for numeric variable comparisons. Chi square test or Fisher’s exact test was 
used for categorical variables whereas appropriate. Multivariate regression analysis was 
used for statistical control or adjustment to assess the independent association between 
variables. All tests are two tailed and p<0.05 was considered as statistically significant.  
 
RESULTS 
Patient demographics 
 Seventy-one patients who underwent robotic proctectomy for rectal 
adenocarcinoma were identified and included in our analysis.  Forty-six patients (65%) 
underwent low anterior resection (LAR) and twenty-five patients (35%) underwent 
abdominal perineal resection (APR).  Patient clinicopathologic characteristics are listed 
in Table 1.  Mean age for the cohort was 63.1 years, 69.0 years for the LAR group, and 
60.0 for the APR group.  Body mass index (BMI) was comparably distributed across the 
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groups.  For the full cohort, 45 patients (63%) were male with 27 (59%) in the LAR 
group and 18 (72%) in the APR group being male. Patient comorbid conditions including 
smoking history, diabetes mellitus, congestive heart failure, chronic obstructive 
pulmonary disease (COPD), functional status, preoperative weight loss of greater than 
10%, serum albumin, and serum hematocrit are listed in Table 1 with no significant 
differences existing between the LAR and APR groups. 
Surgical and Postoperative Outcomes 
 The median operative time for robotic proctectomy was 219 minutes with 
interquartile range (IQR) of 184 minutes to 275 minutes.  Median operative time was 237 
in the APR group (IQR 182.5-297 minutes) and 208 minutes for the LAR group (IQR 
184-261 minutes).  Over the study period, a total of 3 operations (4%) were converted to 
open, which were all patients undergoing LAR and representing 7% of that group.  Mean 
estimated blood loss for the cohort was 164.9 cc (SD 155.9).  Following robotic 
proctectomy, median length of stay was 6 days (IQR 4-8 days) for the entire cohort and 5 
(IQR 4-8) and 6 (IQR 4.5-9) days for the LAR and APR groups respectively.  The 
superficial surgical site infection rate was 7% (n=3) in the LAR group and 4% (n=1) in 
the APR group for an aggregate rate of 6% (n=4).  There was one patient (4%) in the 
APR group that had a deep surgical site infection.  Deep organ space infections occurred 
in 3 patients (7%) in the LAR group and 2 (8%) patients in the APR group.  Two patients 
required return to the operating room, both in the APR group (2/25, 8%), one for 
debridement of a perineal wound and one for evacuation of a pelvic hematoma.  There 
were no anastomotic leaks in the LAR group.  Additionally, in this study, there were no 
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ureteral injuries, urinary tract infections, blood transfusions or mortalities in the 30-day 
postoperative period.   
Tumor and oncologic characteristics 
 Tumor characteristics, pathologic quality, and oncologic outcomes are shown in 
Table 3.  Tumor location was relatively evenly distributed in the LAR group between the 
upper, mid, and lower rectum, and all patients who underwent APR had a tumor in the 
lower rectum.  Twenty-nine patients (63%) in the LAR group and 21 patients (84%) in 
the APR group underwent neoadjuvant chemoradiation for a total rate of 70%.  
Pretreatment stage and final pathologic stage is shown in Table 3.  The circumferential 
radial margin (CRM) was negative in 70/71 (99%) specimens, 26/26 (100%) LAR and 
24/25 (96%) APR.  The mean CRM distance was 16.8 mm (SD 8.9 mm) for LAR 
specimens and 7.6 mm (SD 6.5 mm) for APR specimens.  The average number of lymph 
nodes retrieved was 16.8 (SD 8.9) in LAR specimens and 13.6 (SD 7.1) in APR 
specimens.  Total mesorectal excision (TME) integrity as graded by the pathologist was 
complete or near complete in 23/23 (100%) of graded LAR specimens and 15/16 (94%) 
of graded APR specimens for a total rate of 38/39 (97%).  The median follow up for the 
cohort was 17.1 months (Range 0.7 – 53.2 months).  There were no documented local 
recurrences in either surgical group over the study period.  Fifty-nine patients (83%) in 
our study cohort were alive at last follow up with no evidence of disease.  Eight patients 
(11%) were alive with metastatic disease and one patient (1%) died due to cancer.  
Kaplan-Meier survival estimates are shown for overall survival (Figure 1) and for disease 
free survival (Figure 2).  At five years, disease free survival was 83.1% and overall 
survival was 94.4%.
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DISCUSSION 
 Despite rapidly expanding robotic technology and increased integration of robotic 
surgery into colorectal practices throughout the country, there have not been large 
generalizable studies regarding robotic proctectomy for rectal cancer outside of 
specialized robotics centers.  In this study we report the introduction of robotic 
proctectomy for rectal cancer into a typical colorectal surgeon’s practice at a single 
university center.  Over the first four years of experience robotic proctectomy was 
performed with a low conversion rate, low complication rate, and satisfactory oncologic 
outcomes.  
 The safe dissemination of new techniques, such as robotic proctectomy for rectal 
cancer, into the generalizable surgeons’ practice is an area of important debate [10].  
Factors to be considered begin with oncologic safety, but can extend to attitudes by 
surgeons towards the new technology and techniques, market forces, and how to address 
the conundrum of safe post-graduate surgical training.  In this study we report a low 
complication rate, however, this should be viewed in light of the limitations of the NSQIP 
data set for capturing complications, which could result in more frequent adverse events 
including urinary retention that are not reported here.  This case series highlights both the 
need for further study in the adaption of robotics in rectal cancer surgery and the 
accomplishment of oncologic safety in the practice of a generalizable colorectal surgeon. 
The ability to perform a reproducibly sound oncologic operation is paramount for 
the introduction of robotic proctectomy into a practice for rectal cancer.  We looked at 
three variables in the specimen to evaluate the adequacy of resection.  First, the 
circumferential radial margin (CRM), which was negative in 70/71 (99%) patients, and 
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mean CRM distance was 9.1 mm.  These results are similar to a recent study of robotic 
proctectomy that reported a 5% rate of positive CRM [2] and other previous studies [1-3, 
11-13].  Second, we looked at number of lymph nodes retrieved, which had a mean of 
15.7 lymph nodes, which is within the range of 13.0-17.5 previously reported [11, 14, 
15].  Finally, the integrity of the total mesorectal excision (TME) grade was available in 
39 cases with a complete or near complete grade in 38/39 (97%) patients.  These results 
are comparable to resection characteristics from previous trials, including the CLASICC 
and COREAN trials, comparing laparoscopic and open proctectomy [6, 16-18].  
 Recently, all minimally invasive resection for rectal cancer has been questioned 
based on two randomized trials that both failed to meet non-inferiority criteria for 
laparoscopic resection versus open resection [6, 7].  The primary endpoints for these 
trials were defined as successful resection which included CRM, distal margin, and 
completeness of TME.  The long-term consequence of these oncologic outcomes in the 
neoadjuvant chemoradiation era is incompletely understood and long-term follow up and 
quantification of recurrence and survival rates will be needed to assess the true oncologic 
adequacy of laparoscopic proctectomy. Proponents of robotic surgery have argued that its 
potential advantages, including 3-dimensional optical view, fixed third arm retraction, 
and wristed instrumentation, might overcome some of the limitations responsible for the 
inferiority of minimally-invasive proctectomy in these trials.  However, the results 
presented thus far from the ROLARR trial, which randomized patients to laparoscopic 
versus robotic proctectomy, did not demonstrate any meaningful differences in 
pathologic or clinical outcomes [19]. 
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 Our results must be viewed in light of several limitations and key questions 
remain for robotic proctectomy for rectal cancer.  We presented a single surgeon 
experience, that while independent and self-taught, did represent an academic practice 
where the surgeon had extensive laparoscopy colorectal training as part of traditional 
residency and fellowship training and these factors may limit the generalizability of the 
experience to non-fellowship trained, private practice surgeons.  Additionally, further 
study is needed to determine the costs associated with robotic proctectomy and this data 
was not collected in this review.  
In conclusion we present a case series review of 71 robotic proctectomies for 
rectal cancer with a low conversion rate, low complication rate, and satisfactory 
oncologic outcomes.  Our results demonstrate the successful incorporation of robotic 
proctectomy for rectal cancer into a typical colorectal practice by a single surgeon with 
good procedural and oncologic outcomes, and highlight the need for feedback and audit 
of this process as this technology becomes more widely adopted. 
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Figure 1.  Kaplein-Meier plot demonstrating overall survival. 
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Figure 2.  Kaplein-Meier plot demonstrating disease-free survival. 
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Table 1. Clinicopathologic Characteristics of study population 
 
 
Characteristic, n (%) 
LAR 
n=46 
APR 
n=25 
All 
N=71 
Age in years, mean+ SD 60.0±13.1 69.0±12.9 63.1±13.7 
Body Mass Index (BMI), mean+ SD 
     <18.0 
     18.1-29.9 
     30.0-34.9 
     35.0-39.9 
     > 40.0 
26.4±5.0 
2(4%) 
31(67%) 
10(22%) 
3(7%) 
0(0%) 
29.2±8.3 
2(8%) 
13(52%) 
6(24%) 
1(4%) 
3(12%) 
27.4±6.4 
4(6%) 
44(62%) 
16(23%) 
4(6%) 
3(4%) 
Male gender 27(59%) 18(72%) 45(63%) 
ASA Classification 
1-2 
3 
4 
 
31(67%) 
13(28%) 
2(4%) 
 
12(48%) 
13(52%) 
0(0%) 
 
43(60%) 
26(37%) 
2(3%) 
Patient Smoking History 13(28%) 9(36%) 22(31%) 
Diabetes mellitus 5(11%) 4(16%) 9(13%) 
Congestive Heart Failure 0(0%) 0(0%) 0(0%) 
Chronic Obstructive Pulmonary Disease 4(9%) 1(4%) 5(7%) 
Functional status; dependent 1(2%) 1(4%) 2(3%) 
Weight loss >10% 4(9%) 2(8%) 6(8%) 
Albumin g/dL, mean+ SD (n=49 ) 4.0±0.5 3.9±0.3 4.0±0.5 
Hematocrit g/dL, mean+ SD  39.5±4.5 39.2±3.8 39.4±4.2 
 
 
LAR= Low anterior resection with ileostomy or colostomy or anterior resection without 
proximal diversion; APR= Abdominal Perineal Resection; ASA= American Society of 
Anesthesiologist 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved.
17 
 
Table 2. Surgical and Postoperative Outcomes 
 
LAR= Low anterior resection with ileostomy or colostomy or anterior resection without 
proximal diversion; APR= Abdominal Perineal Resection; UTI=Urinary Tract Infection; 
SSI-Surgical Site Infection. IQR=Interquartile range 
 
 
 
 
 
 
 
 
 
 
 
 
Outcome 
LAR 
n=46 
APR 
n=25 
All 
N=71 
Procedure time in minutes 
(median&IQR) 208(184-261) 237(182.5-297) 219(184-275) 
Conversion: n (%) 
 
3(7%) 0(0%) 3(4%) 
Estimated Blood loss (cc), 
Mean+ SD 
128.5±142.6 237.7±161.2 164.9±155.9 Ureteral injury 0 (0%) 0 (0%) 0 (0%) Length of stay (LOS) in days (median&IQR) 5(4-8) 6(4.5-9) 6(4-8) 
30 day Mortality 0 (0%) 0 (0%) 0 (0%) 
UTI 0 (0%) 0 (0%) 0 (0%) 
Superficial SSI n(%) 3(7%) 1(4%) 4(6%) 
Deep SSI n(%) 0 (0%) 1(4%) (1%) 
Organ space SSI n(% 3(7%) 2(8%) 5(7%) 
Transfusion 0 (0%) 0 (0%) 0 (0%) 
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Table 3. Tumor and Oncologic Characteristics 
 
LAR= Low anterior resection with ileostomy or colostomy or anterior resection without 
proximal diversion; APR= Abdominal Perineal Resection; CRM=Circumferential Radial 
Margin; TME=Total Mesorectal Excision; NED=No evidence of Disease, 
IQR=Interquartile range. 
 
 
 
Outcome 
LAR 
n=46 
APR 
n=25 
All 
N=71 
Tumor Location 
     Upper Rectum (>10cm) 
     Mid Rectum (6-9cm) 
     Lower Rectum (< 5 cm) 
 
11(24%) 
15(33%) 
20(43%) 
 
0(0%) 
0(0%) 
25(100%) 
 
11(15%) 
15(21%) 
45(63%) 
Pretreatment Stage 
     I 
     II 
     III 
     IV 
 
15(33%) 
11(24%) 
20(43%) 
0 (0%) 
 
4(16%) 
3(12%) 
18(72%) 
0 (0%) 
 
19(27%) 
14(20%) 
38(54%) 
0 (0%) 
Neoadjuvant Chemoradiation 29(63%) 21(84%) 50(70%) 
Pathologic stage 
    0 
    I 
    II 
    III 
    IV 
 
2(4%) 
22(48%) 
9(20%) 
13(28%) 
0 (0%) 
 
4(16%) 
6(24%) 
3(12%) 
12(48%) 
0 (0%) 
 
6(8%) 
28(39%) 
12(17%) 
25(35%) 
0 (0%) 
CRM – negative n(%) 
 
CRM Distance (mm), Mean+ SD  
46(100%) 
 
10.1±5.5 
24(96%) 
 
7.6±6.5 
70(99%) 
 
9.1±6.0 
Lymph Nodes retrieved, Mean+ SD 16.8±8.9 13.6±7.1 15.7±8.4 
TME integrity (n=39) 
     Complete/Near Complete 
     Incomplete 
 
23(100%) 
0(0%) 
 
15(94%) 
1(6%) 
 
38(97%) 
1(3%) 
Follow up (Months, median & IQR) 
Alive (NED) 
Alive with disease 
Death due to cancer 
Death due to other cause 
Local Recurrence 
17.3(11.1-32.7) 
37(80%) 
6(13%) 
 1(2%) 
2(4%) 
0(0%) 
14.5(7.9-36.0) 
22(88%) 
2(8%) 
0(0%) 
1(4%) 
0(%) 
17.3(10.6-34.5) 
59(83%) 
8(11%) 
      1(1%) 
3(4%) 
0(0%) 
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